Acurx Pharmaceuticals (ACXP) Awarded New Australian Patent for Antibiotic Innovation

Biotech investors and pharmaceutical innovators: Acurx Pharmaceuticals (NASDAQ: ACXP), a late-stage biopharma company developing next-generation antibiotics for difficult-to-treat infections, has been granted a new patent by the Australian Patent Office.

📌 Key Highlights:

Patent covers DNA polymerase inhibitors & compositions of matter

Expands IP protection for Acurx’s antimicrobial platform

Adds to existing patents in U.S., Israel, Japan, and India

Reinforces global leadership in small molecule antibiotic development

This milestone strengthens Acurx’s mission to combat antibiotic resistance and advance innovative treatments worldwide.

🔖 YouTube Tags:

#AcurxPharmaceuticals #ACXP #Antibiotics #BiotechInvesting #PatentNews #AntimicrobialResistance #DrugDevelopment #PharmaInnovation #GlobalPatents #HealthcareInnovation #NewsOut #JaneKing #NasdaqACXP